- Molecular NameFosphenytoin
- Synonym(3-Phosphoryloxymethyl)phenytoin; Fosfenitoina [inn-spanish]; Fosphenytoin sodium; Fosphenytoine [inn-french]; Fosphenytoinum [inn-latin]
- Weight362.278
- Drugbank_IDDB01320
- ACS_NO93390-81-9
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)0.06
- pka8.06 to 8.33
- LogD (pH=7, predicted)-4.51
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)0.44
- LogSw (predicted, AB/LogsW2.0)1.39
- Sw (mg/ml) (predicted, ACD/Labs)3.09
- No.of HBond Donors3
- No.of HBond Acceptors8
- No.of Rotatable Bonds5
- TPSA125.98
- StatusFDA approved
- AdministrationIntravenous, intramuscular
- PharmacologyA water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- BioavailabilityN/A
- Protein binding94.5
- Volume of distribution (VD)0.6~0.7 L/kg (Adults and children), 0.7~0.7 L/kg (infants), 0.8~0.9 L/kg (full term neonates) and 1~1.2 L/kg (premature neonates)
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmFosphenytoin sodium is rapidly and completely metabolised to phenytoin and other metabolites including phosphate and formaldehyde which are subsequently converted to formate and further metabolites. Phenytoin is metabolised to 5-(p-hydroxyphenyl)-5-phenylhydantoin.
- Half life0.55 h (Intramuscular administration), 8 min ((intravenous administration))
- ExcretionThe metabolites are excreted in urine. It is distributed in cerebrospinal fluid, saliva, semen, gastro-intestinal fluids, bile and breast milk.
- Urinary ExcretionN/A
- Clerance19.8 L/h.
- ToxicityThe blood toxic range is 30 to 50 mg/L and a concentration of >100 mg/L has been associated with fatalities. Acute hepatotoxicity and hypersensitivity reactions have been observed and phenytoin and the other metabolites may result in toxicity after overdosing, including hypotension, coma and respiratory or circularity depression which may be fatal.
- LD50 (rat)N/A
- LD50 (mouse)N/A